GGrantIndex
← Leaderboards

Ashim K Mitra

University Of Missouri Kansas City

$7,598,024
Attributed
$7,598,024
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1M · FY200511
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11

Funding mix

By agency

NIH$7,598,024 · 4

By mechanism

R01$7,598,024 · 4

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “Prodrugs

Research focus

ProdrugsMicrodialysisDrug Screening /EvaluationDrug Design /Synthesis /ProductionUptakeSolubilityIn VivoPeptidesBiological AvailabilityAmino AcidsAntiviral AgentsPermeabilityPharmaceutical PreparationsDesignMediatingLaboratory RabbitPharmacokineticsDrug Delivery SystemsCytotoxicityPropertyIn VitroAcyclovirDrug MetabolismDrug Resistance

Grant awards (28)

Protease Inhibitor Analogues for Enhanced Transport Across Blood-Brain Interfaces$365,087
R01 · FY2011 · AI · contact PI
Protease Inhibitor Analogues for Enhanced Transport Across Blood-Brain Interfaces$368,775
R01 · FY2010 · AI · contact PI
Transscleral Transport & Polymeric Delivery of Antibody & Steroids for Macular Ed$331,898
R01 · FY2010 · EY · contact PI
Ocular Disposition of Antimicrobial Agents$297,615
R01 · FY2010 · EY · contact PI
Protease Inhibitor Analogues for Enhanced Transport Across Blood-Brain Interfaces$372,500
R01 · FY2009 · AI · contact PI
Transscleral Transport & Polymeric Delivery of Antibody & Steroids for Macular Ed$335,250
R01 · FY2009 · EY · contact PI
Ocular Disposition of Antimicrobial Agents$300,622
R01 · FY2009 · EY · contact PI
Protease Inhibitor Analogues for Enhanced Transport Across Blood-Brain Interfaces$372,500
R01 · FY2008 · AI · contact PI
Transscleral Transport & Polymeric Delivery of Antibody & Steroids for Macular Ed$335,250
R01 · FY2008 · EY · contact PI
Ocular Disposition of Antimicrobial Agents$294,609
R01 · FY2008 · EY · contact PI
Ocular Disposition of Antimicrobial Agents$300,622
R01 · FY2007 · EY · contact PI
Ocular Disposition of Antimicrobial Agents$320,175
R01 · FY2006 · EY · contact PI
Antiviral Drug Kinetics in Vitreous Using Microdialysis$212,389
R01 · FY2006 · EY · contact PI
Ocular Disposition of Acycloguanosine Analogues$267,478
R01 · FY2005 · EY
Antiviral Drug Kinetics in Vitreous Using Microdialysis$217,500
R01 · FY2005 · EY
Ocular Disposition of Acycloguanosine Analogues$267,478
R01 · FY2004 · EY
Antiviral Drug Kinetics in Vitreous Using Microdialysis$217,500
R01 · FY2004 · EY
Cellular Efflux and Metabolism of Protease Inhibitors$203,000
R01 · FY2004 · GM
Ocular Disposition of Acycloguanosine Analogues$267,478
R01 · FY2003 · EY
Antiviral Drug Kinetics in Vitreous Using Microdialysis$217,500
R01 · FY2003 · EY
Cellular Efflux and Metabolism of Protease Inhibitors$203,000
R01 · FY2003 · GM
Ocular Disposition of Acycloguanosine Analogues$278,728
R01 · FY2002 · EY
ANTIVIRAL DRUG KINETICS IN VITREOUS USING MICRODIALYSIS$209,218
R01 · FY2002 · EY
Cellular Efflux and Metabolism of Protease Inhibitors$203,000
R01 · FY2002 · GM
OCULAR DISPOSITION OF ACYCLOGUANOSINE ANALOGUES$222,498
R01 · FY2001 · EY
ANTIVIRAL DRUG KINETICS IN VITREOUS USING MICRODIALYSIS$203,125
R01 · FY2001 · EY
OCULAR DISPOSITION OF ACYCLOGUANOSINE ANALOGUES$216,020
R01 · FY2000 · EY
ANTIVIRAL DRUG KINETICS IN VITREOUS USING MICRODIALYSIS$197,209
R01 · FY2000 · EY